Lonza Group AG (LZAGY) Stock Analysis & Winston Score

Lonza Group is a Swiss company that makes the ingredients and finished products inside medicines — not the medicines themselves. It acts as a "factory for hire" for pharmaceutical and biotech companies, helping them manufacture drugs, including many biologics (medicines made from living cells) and cell and gene therapies. Lonza is one of the largest contract drug manufacturers in the world, serving major pharmaceutical companies like Moderna, Roche, and Novartis. The company earns money by charging clients fees to use its manufacturing facilities and scientific expertise, a model known as contract development and manufacturing (CDMO). Lonza operates large facilities across Europe, the United States, and Asia, and generates roughly $6–7 billion in annual revenue. Its moat comes from the complexity and regulatory difficulty of building competing facilities, which takes years and billions of dollars. The key risk is customer concentration — losing a major contract, as happened when Moderna reduced its COVID vaccine orders, can meaningfully hurt revenue.